Scarica l'app Stockscreener
1.90
7.34%
0.13
Tvardi Therapeutics Inc Borsa (TVRD) Ultime notizie
Tvardi Reports $6.5 Million Second-Quarter Net Loss and TTI-109 UC Plans - Moomoo
Tvardi Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Tvardi Q2 net loss reaches $6.5 million - grafa.com
Tvardi Therapeutics Reports Q2 2026 Net Loss of $6.5 Million - Minichart
Tvardi Q2 EPS $(0.69) beats $(0.70) estimate, loss narrows 31% - scanx.trade
Form 8K Tvardi Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Tvardi Therapeutics, Inc. 2026: Revenue ($6.46M), EPS ($0.69) — 10-Q Summary - TradingView
Tvardi Reports Positive TTI-109 Data, Picks Ulcerative Colitis for Next-Gen Drug - Minichart
Tvardi Therapeutics: Q2 2026 saw a $6.5M net loss, cash of $15.8M, and urgent need for additional funding - TradingView
Tvardi posts Q2 2026 net loss of $6.5M, cash $15.8M; reports TTI-109 healthy volunteer topline - TradingView
Tvardi Therapeutics: TTI-109 advanced for UC after positive topline results; Q2 net loss was $6.5 million - TradingView
Tvardi: Q2 Earnings Snapshot - 10TV
BRIEF-Tvardi Therapeutics Inc Q2 Net Income USD -6.5 Million Vs. IBES Estimate USD -6.54 Million - TradingView
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update - GlobeNewswire
Tvardi Therapeutics to Host KOL Webinar on the Clinical - GlobeNewswire
JonesTrading Maintains Tvardi Therapeutics(TVRD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Tvardi Therapeutics, Inc. Revenue Breakdown – NASDAQ:TVRD - TradingView
Tvardi Therapeutics, Inc. expected to post a loss of 70 cents a shareEarnings Preview - TradingView
Tvardi Therapeutics Ord Shs (TVRD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to revenue forward of Tvardi Therapeutics Inc. – FWB:69C - TradingView
TVRD Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109, Plans 2027 Clinical Trial - Quiver Quantitative
Tvardi's TTI-109 Shows Up to 76% Immune-Cell Reduction in Phase 1 - Stock Titan
Tvardi Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Pipeline ProgressEarnings Manipulation Risk - dars.gov.et
TVRD|Tvardi Therapeutics Ord Shs|Price:2.555|Chg%:+0.045 - TradingKey
Tvardi Therapeutics Ord Shs (TVRD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tvardi Therapeutics Ord Shs (TVRD) Institutional Confidence - TradingKey
Tvardi Therapeutics (TVRD) Edges Higher, Testing Key Resistance LevelsCounter Trend Trade - dars.gov.et
Tvardi Therapeutics Inc. Revenue Breakdown – LS:A414VY - TradingView
Tvardi Therapeutics Inc. Revenue Breakdown – LSX:A414VY - TradingView
Tvardi Therapeutics, Inc. (NASDAQ: TVRD) Share Price, TVRD Stock News, TVRD Share Price & Updates - Kalkine
Tvardi Therapeutics Company Profile & Introduction - Moomoo
ONDS: Ondas Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Tvardi Therapeutics Expands At-The-Market Equity Program - The Globe and Mail
Form 424B5 Tvardi Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
Tvardi Therapeutics | 8-K: Current report - Moomoo
Tvardi Therapeutics (NASDAQ: TVRD) adds $9.69M capacity to ATM program - Stock Titan
Tvardi Therapeutics (TVRD) plans up to $9.7M Nasdaq at-the-market stock offering - Stock Titan
Tvardi Therapeutics | 424B5: Prospectus - Moomoo
Tvardi Therapeutics expands ATM program by $9.69M after prior $11.0M sales under JonesTrading - TradingView
symbol__ Stock Quote Price and Forecast - CNN
TVRD stock rallies 149% so far this week: Here's what you should know - MSN
Enterprise value to revenue forward of Tvardi Therapeutics Inc. – BX:TVRD - TradingView
Tvardi Therapeutics(TVRD) Stock Options Chain | Quotes & News - Moomoo
Tvardi Therapeutics (TVRD) Proxy filing Summary - Quartr
Tvardi Therapeutics (TVRD) Registration filing Summary - Quartr
Tvardi Therapeutics (TVRD) Company presentation Summary - Quartr
Tvardi Therapeutics (TVRD) Registration Filing Summary - Quartr
Tvardi Therapeutics (TVRD) Q4 2025 earnings summary - Quartr
Tvardi Therapeutics (TVRD) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Tvardi Therapeutics (TVRD) Slides 3.68% as Stock Tests Key Support LevelsCatalyst Driven Stocks - dars.gov.et
$Tvardi Therapeutics (TVRD.US)$ Respect it & it will Respect you - Moomoo
Why Is Tvardi Therapeutics Stock Falling Thursday? - MSN
TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know - Yahoo Finance
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):